# ANTES B+ Clinical Trial

> **NCT06282861** · PHASE4 · TERMINATED · sponsor: **Fundacio Privada Mon Clinic Barcelona** · enrollment: 48 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Trelegy Ellipta 100/62.5/25Mcg Inh 30D
- **DRUG:** Brimica
- **DRUG:** Duaklir
- **DRUG:** Ultibro
- **DRUG:** Ulunar
- **DRUG:** Xoterna
- **DRUG:** Anoro
- **DRUG:** Laventair
- **DRUG:** Spiolto Respimat
- **DRUG:** Yanimo
- **DRUG:** Foradil
- **DRUG:** Broncoral
- **DRUG:** Formoterol stada
- **DRUG:** Oxis
- **DRUG:** Formatris
- **DRUG:** Formoterol Aldo
- **DRUG:** Onbrez
- **DRUG:** Oslif
- **DRUG:** Hirobriz
- **DRUG:** Striverdi

## Key facts

- **NCT ID:** NCT06282861
- **Lead sponsor:** Fundacio Privada Mon Clinic Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-29
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-01-23
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06282861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06282861, "ANTES B+ Clinical Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06282861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*